We are live on
!
Find out more
RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$810M
1-Year Est. Return
30.2%
This Fund
S&P 500
This Quarter
Est. Return
+6.63%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$256M
AUM Growth
–
Cap. Flow
+$245M
Cap. Flow
% of AUM
96.01%
Top 10 Holdings %
Top 10 Hldgs %
29.36%
Holding
84
New
84
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$10.6M |
| 2 |
CELG
Celgene Corp
CELG
|
+$7.75M |
| 3 |
Gilead Sciences
GILD
|
+$7.59M |
| 4 |
PCYC
PHARMACYCLICS INC
PCYC
|
+$7.28M |
| 5 |
Biogen
BIIB
|
+$6.98M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 82.65% |
| 2 | Financials | 1.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Regeneron Pharmaceuticals
REGN
$78.5B
| $10.2M | 3.98% |
+37,000
| New | +$10.6M |
|
|
CELG
2
DELISTED
Celgene Corp
CELG
| $8.28M | 3.24% |
+98,000
| New | +$7.75M |
|
|
3
Gilead Sciences
GILD
$162B
| $8.19M | 3.2% |
+109,000
| New | +$7.59M |
|
4
CVS Health
CVS
$133B
| $7.66M | 3% |
+107,000
| New | +$6.87M |
|
|
5
Biogen
BIIB
$30B
| $7.55M | 2.95% |
+27,000
| New | +$6.98M |
|
|
NPSP
6
DELISTED
NPS PHARMACEUTICALS INC
NPSP
| $7.29M | 2.85% |
+240,000
| New | +$6.61M |
|
7
BioMarin Pharmaceuticals
BMRN
$11.6B
| $7.03M | 2.75% |
+100,000
| New | +$6.79M |
|
|
ALXN
8
DELISTED
Alexion Pharmaceuticals
ALXN
| $6.65M | 2.6% |
+50,000
| New | +$6M |
|
|
PCYC
9
DELISTED
PHARMACYCLICS INC
PCYC
| $6.35M | 2.48% |
+60,000
| New | +$7.28M |
|
10
Alkermes
ALKS
$8.22B
| $5.9M | 2.31% |
+145,000
| New | +$5.35M |
|
|
AEGR
11
DELISTED
Aegerion Pharmaceuticals
AEGR
| $5.32M | 2.08% |
+75,000
| New | +$5.74M |
|
|
KERX
12
DELISTED
Keryx Biopharmaceuticals Inc
KERX
| $5.18M | 2.03% |
+400,000
| New | +$4.78M |
|
|
SLXP
13
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
| $4.95M | 1.94% |
+55,000
| New | +$4.39M |
|
|
ARIA
14
DELISTED
Ariad Pharmaceuticals Inc
ARIA
| $4.77M | 1.87% |
+700,000
| New | +$3.78M |
|
15
Innoviva
INVA
$1.55B
| $4.71M | 1.84% |
+163,812
| New | +$4.79M |
|
16
CALL
Johnson & Johnson
JNJ
$618B
| $4.58M | 1.79% |
+50,000
| New | +$4.61M |
|
|
ESRX
17
DELISTED
Express Scripts Holding Company
ESRX
| $4.57M | 1.79% |
+65,000
| New | +$4.24M |
|
18
Incyte
INCY
$24.2B
| $4.3M | 1.68% |
+85,000
| New | +$3.7M |
|
19
Medtronic
MDT
$109B
| $4.3M | 1.68% |
+75,000
| New | +$4.25M |
|
20
Merck
MRK
$322B
| $4.25M | 1.66% |
+89,080
| New | +$4.07M |
|
21
Bristol-Myers Squibb
BMY
$133B
| $3.83M | 1.5% |
+72,000
| New | +$3.67M |
|
22
UnitedHealth
UNH
$376B
| $3.31M | 1.3% |
+44,000
| New | +$3.16M |
|
23
Boston Scientific
BSX
$69.5B
| $3.31M | 1.29% |
+275,000
| New | +$3.25M |
|
|
FRX
24
DELISTED
FOREST LABORATORIES INC
FRX
| $3.3M | 1.29% |
+55,000
| New | +$2.77M |
|
25
Intuitive Surgical
ISRG
$127B
| $3.07M | 1.2% |
+72,000
| New | +$3.03M |
|
Similar funds
BBI
SSG
PS
ACM
AR
DWA
SLG
KCP
Rhenman & Partners Asset Management's Q4 2013 Portfolio in Review
Q4 2013 is the first quarter with a 13F filing on record for Rhenman & Partners Asset Management, which disclosed 84 positions worth $256M. Its ten largest holdings account for 29% of the portfolio.
Its largest position is Regeneron Pharmaceuticals: 37,000 shares worth $10.2M.
By sector, the portfolio is most concentrated in Healthcare at 83% of assets, followed by Financials.
- Rhenman & Partners Asset Management's largest Q4 2013 buy was Regeneron Pharmaceuticals: 37,000 shares worth $10.2M.
- Rhenman & Partners Asset Management's ten largest holdings make up 29% of its $256M portfolio in Q4 2013.
- Rhenman & Partners Asset Management disclosed 84 positions in Q4 2013, its first 13F filing on record.
Based on Rhenman & Partners Asset Management's 13F filing for Q4 2013, filed 14 Feb 2014.